Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1973 Sep;4(3):281–284. doi: 10.1128/aac.4.3.281

Studies on the Susceptibility of 150 Consecutive Clinical Isolates of Pseudomonas aeruginosa to Tobramycin, Gentamicin, Colistin, Carbenicillin, and Five Other Antimicrobials

W R Lockwood 1,2, Lucy A Lawson 1,2
PMCID: PMC444542  PMID: 4202342

Abstract

The in vitro susceptibilities of 150 clinical isolates of Pseudomonas aeruginosa to the aminoglycoside tobramycin and eight other antimicrobials were evaluated. The Food and Drug Administration standardized disk diffusion method showed that tobramycin inhibited 100% of the 150 isolates with gentamicin inhibiting only 90.7%. The difference between colistin (97.3%) and tobramycin was less marked. Carbenicillin (87.3%) was found to be slightly less active than gentamicin. Only a small percentage of the isolates were inhibited by the other drugs used. By using a minimal inhibitory concentration of 4 μg/ml in brain heart infusion broth as the level of susceptibility, it was found that only three of the isolates showed resistance to tobramycin, whereas 20 of the isolates were resistant to gentamicin. Approximately half of the isolates were inhibited by 0.5 μg/ml or less of tobramycin, whereas 1.5 μg of gentamicin per ml was required to inhibit 50% of susceptible strains.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler J. L., Finland M. Susceptibility of recent isolates of Pseudomonas aeruginosa to gentamicin, polymyxin, and five penicillins, with observations on the pyocin and immunotypes of the strains. Appl Microbiol. 1971 Nov;22(5):870–875. doi: 10.1128/am.22.5.870-875.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  3. Black H. R., Griffith R. S. Preliminary studies with nebramycin factor 6. Antimicrob Agents Chemother (Bethesda) 1970;10:314–321. [PubMed] [Google Scholar]
  4. Britt M. R., Garibaldi R. A., Wilfert J. N., Smith C. B. In vitro activity of tobramycin and gentamicin. Antimicrob Agents Chemother. 1972 Sep;2(3):236–241. doi: 10.1128/aac.2.3.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brusch J. L., Barza M., Bergeron M. G., Weinstein L. Cross-resistance of Pseudomonas to gentamicin and tobramycin. Antimicrob Agents Chemother. 1972 Mar;1(3):280–281. doi: 10.1128/aac.1.3.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davis S. D., Iannetta A., Wedgwood R. J. Antibiotics for Pseudomonas aeruginosa sepis: inadequate proof of efficacy. J Infect Dis. 1971 Jul;124(1):104–106. doi: 10.1093/infdis/124.1.104. [DOI] [PubMed] [Google Scholar]
  7. Del Bene V. E., Farrar W. E., Jr Tobramycin: in vitro activity and comparison with kanamycin and gentamicin. Antimicrob Agents Chemother. 1972 Apr;1(4):340–342. doi: 10.1128/aac.1.4.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dienstag J., Neu H. C. In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972 Jan;1(1):41–45. doi: 10.1128/aac.1.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. KING E. O., WARD M. K., RANEY D. E. Two simple media for the demonstration of pyocyanin and fluorescin. J Lab Clin Med. 1954 Aug;44(2):301–307. [PubMed] [Google Scholar]
  10. Levison M. E., Knight R., Kaye D. In vitro evaluation of tobramycin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972 May;1(5):381–384. doi: 10.1128/aac.1.5.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Meyer R. D., Young L. S., Armstrong D. Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol. 1971 Dec;22(6):1147–1151. doi: 10.1128/am.22.6.1147-1151.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Meyers B. R., Hirschman S. Z. Pharmacologic studies on tobramycin and comparison with gentamicin. J Clin Pharmacol New Drugs. 1972 Aug-Sep;12(8):321–324. doi: 10.1002/j.1552-4604.1972.tb00174.x. [DOI] [PubMed] [Google Scholar]
  13. Preston D. A., Wick W. E. Preclinical assessment of the antibacterial activity of nebramycin factor 6. Antimicrob Agents Chemother (Bethesda) 1970;10:322–327. doi: 10.1128/AAC.10.2.322. [DOI] [PubMed] [Google Scholar]
  14. Shadomy S., Kirchoff C. In vitro susceptibility testing with tobramycin. Antimicrob Agents Chemother. 1972 May;1(5):412–416. doi: 10.1128/aac.1.5.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Thompson R. Q., Presti E. A. Nebramycin, a new broad-spectrum antibiotic complex. 3. Isolation and chemical-physical properties. Antimicrob Agents Chemother (Bethesda) 1967;7:332–340. [PubMed] [Google Scholar]
  16. Traub W. H., Raymond E. A. Evaluation of the in vitro activity of tobramycin as compared with that of gentamicin sulfate. Appl Microbiol. 1972 Jan;23(1):4–7. doi: 10.1128/am.23.1.4-7.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Traub W. H. Susceptibility of Pseudomonas aeruginosa to gentamicin sulfate in vitro: lack of correlation between disc diffusion and broth dilution sensitivity data. Appl Microbiol. 1970 Jul;20(1):98–102. doi: 10.1128/am.20.1.98-102.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES